Cognitive Decline in Mild Alzheimer’s Slowed with Azeliragon

Cognitive Decline in Mild Alzheimer’s Slowed with Azeliragon
Data from a Phase 2b clinical trial showing that  vTv Therapeutics's investigational drug, azeliragon, slows cognitive decline in patients with mild Alzheimer’s disease were presented at the Alzheimer's Association International Conference 2016 in Toronto this week. Azeliragon is a drug that blocks the receptor RAGE (Receptor for Advanced Glycation Endproducts) in the brain. Normally found in low numbers in a healthy brain, RAGE numbers increase during inflammation. Examinations of deceased Alzheimer’s patients indicate that RAGE numbers seem to correlate with disease severity and progression. The higher number affects both neurons and glial cells in the brain, and is linked t
Subscribe or to access all post and page content.


  1. Diane Neher says:

    My mother is on this study. She’s into the 2 year mark and is on the real medicine. I’m concerned because her confusion has increased surmountable since she’s been on the real medicine.

    • Tim Bossie says:

      We are so very sorry to hear that Diane. It is incredibly hard to see our loved ones, especially our parents or our children, suffer with a disease that we can’t help them with.

Leave a Comment

Your email address will not be published. Required fields are marked *